Literature DB >> 1725692

Differential inhibitory effects of sulfated polysaccharides and polymers on the replication of various myxoviruses and retroviruses, depending on the composition of the target amino acid sequences of the viral envelope glycoproteins.

M Hosoya1, J Balzarini, S Shigeta, E De Clercq.   

Abstract

Sulfated polysaccharides (i.e., dextran sulfate) and sulfated polymers (i.e., sulfated polyvinylalcohol and sulfated copolymers of acrylic acid with vinylalcohol) were found to be potent and selective inhibitors of the replication of respiratory syncytial virus (RSV) and influenza virus type A (influenza A virus) but not of other myxoviruses (parainfluenza 3, measles, and influenza B viruses). The compounds were also inhibitory to human immunodeficiency virus type 1 (HIV-1) and HIV-2 and simian immunodeficiency virus but not simian AIDS-related virus. The mode of antiviral action of the sulfated polysaccharides and polymers can be attributed to an inhibition of virus binding to the cells (HIV-1), inhibition of virus-cell fusion (influenza A virus), or inhibition of both virus-cell binding and fusion (RSV). The fact that the sulfated polysaccharides and polymers are inhibitory to some myxoviruses and retroviruses but not to others seems to depend on the composition of the amino acid sequences of the viral envelope glycoproteins that are involved in virus-cell binding and fusion. All myxoviruses and retroviruses that are sensitive to the sulfated polysaccharides and polymers share a tripeptide segment (Phe-Leu-Gly). This tripeptide segment may be involved either directly (as a target sequence) or indirectly in the inhibitory effects of the compounds on virus-cell binding and fusion.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1725692      PMCID: PMC245423          DOI: 10.1128/AAC.35.12.2515

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  Dextran sulfate inhibits the fusion of influenza virus with model membranes, and suppresses influenza virus replication in vivo.

Authors:  M Lüscher-Mattli; R Glück
Journal:  Antiviral Res       Date:  1990-07       Impact factor: 5.970

2.  Nucleotide sequence of the AIDS virus, LAV.

Authors:  S Wain-Hobson; P Sonigo; O Danos; S Cole; M Alizon
Journal:  Cell       Date:  1985-01       Impact factor: 41.582

3.  Fusion glycoprotein of human parainfluenza virus type 3: nucleotide sequence of the gene, direct identification of the cleavage-activation site, and comparison with other paramyxoviruses.

Authors:  M K Spriggs; R A Olmsted; S Venkatesan; J E Coligan; P L Collins
Journal:  Virology       Date:  1986-07-15       Impact factor: 3.616

Review 4.  The role of viral glycoproteins in adsorption, penetration, and pathogenicity of viruses.

Authors:  P W Choppin; A Scheid
Journal:  Rev Infect Dis       Date:  1980 Jan-Feb

5.  Genome organization and transactivation of the human immunodeficiency virus type 2.

Authors:  M Guyader; M Emerman; P Sonigo; F Clavel; L Montagnier; M Alizon
Journal:  Nature       Date:  1987 Apr 16-22       Impact factor: 49.962

6.  Inhibitory effect of selected antiviral compounds on arenavirus replication in vitro.

Authors:  G Andrei; E De Clercq
Journal:  Antiviral Res       Date:  1990 Oct-Nov       Impact factor: 5.970

7.  Nucleotide sequence of SRV-1, a type D simian acquired immune deficiency syndrome retrovirus.

Authors:  M D Power; P A Marx; M L Bryant; M B Gardner; P J Barr; P A Luciw
Journal:  Science       Date:  1986-03-28       Impact factor: 47.728

8.  Comparative activities of several nucleoside analogs against influenza A, B, and C viruses in vitro.

Authors:  S Shigeta; K Konno; T Yokota; K Nakamura; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

9.  Isolation of T-cell tropic HTLV-III-like retrovirus from macaques.

Authors:  M D Daniel; N L Letvin; N W King; M Kannagi; P K Sehgal; R D Hunt; P J Kanki; M Essex; R C Desrosiers
Journal:  Science       Date:  1985-06-07       Impact factor: 47.728

10.  Antiviral and antimetabolic activities of neplanocins.

Authors:  E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

View more
  26 in total

1.  Capillary endothelial cell tropism of PVC-211 murine leukemia virus and its application for gene transduction.

Authors:  M Masuda; C A Hanson; N V Dugger; D S Robbins; S G Wilt; S K Ruscetti; P M Hoffman
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 2.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

3.  A unique heparin-binding domain in the envelope protein of the neuropathogenic PVC-211 murine leukemia virus may contribute to its brain capillary endothelial cell tropism.

Authors:  A Jinno-Oue; M Oue; S K Ruscetti
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

4.  Pentosan Polysulfate Demonstrates Anti-human T-Cell Leukemia Virus Type 1 Activities In Vitro and In Vivo.

Authors:  Guangyong Ma; Jun-Ichirou Yasunaga; Koichi Ohshima; Tadashi Matsumoto; Masao Matsuoka
Journal:  J Virol       Date:  2019-07-30       Impact factor: 5.103

5.  Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection.

Authors:  L K Hallak; D Spillmann; P L Collins; M E Peeples
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

6.  In vitro and in vivo inhibition of ortho- and paramyxovirus infections by a new class of sulfonic acid polymers interacting with virus-cell binding and/or fusion.

Authors:  S Ikeda; J Neyts; S Verma; A Wickramasinghe; P Mohan; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

7.  RhoA-derived peptide dimers share mechanistic properties with other polyanionic inhibitors of respiratory syncytial virus (RSV), including disruption of viral attachment and dependence on RSV G.

Authors:  Philip J Budge; Yeqiang Li; Judy A Beeler; Barney S Graham
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

8.  Role of cellular glycosaminoglycans and charged regions of viral G protein in human metapneumovirus infection.

Authors:  Sutthiwan Thammawat; Tania A Sadlon; Peter G Hallsworth; David L Gordon
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

9.  Heparin-like structures on respiratory syncytial virus are involved in its infectivity in vitro.

Authors:  C Bourgeois; J B Bour; K Lidholt; C Gauthray; P Pothier
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

10.  Highly sulfated K5 Escherichia coli polysaccharide derivatives inhibit respiratory syncytial virus infectivity in cell lines and human tracheal-bronchial histocultures.

Authors:  Valeria Cagno; Manuela Donalisio; Andrea Civra; Marco Volante; Elena Veccelli; Pasqua Oreste; Marco Rusnati; David Lembo
Journal:  Antimicrob Agents Chemother       Date:  2014-06-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.